Management of Advanced Ovarian Cancer: Current Clinical Practice and Future Perspectives

QR Code

Management of Advanced Ovarian Cancer: Current Clinical Practice and Future Perspectives

Ovarian cancer is the most lethal gynecologic malignancy, which causes 313,959 new cases and 207,252 deaths worldwide annually. The lack of specific symptoms, together with no effective screening tools, results in 75% of patients receiving their diagnosis at an advanced stage. The combination of cyt...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dimitrios Papageorgiou, Galateia Liouta, Evangelia Pliakou, Eleftherios Zachariou, Ioakeim Sapantzoglou, Ioannis Prokopakis, Emmanuel N. Kontomanolis
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Biomedicines
Subjects:	advanced ovarian cancer cytoreductive surgery chemotherapy PARP inhibitors antibody-drug conjugates immunotherapy
Online Access:	https://www.mdpi.com/2227-9059/13/7/1525
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Recent Developments in Rare Ovarian Carcinosarcoma: Literature Review and Case Report
by: Alexandra Nienhaus, et al.
Published: (2025-05-01)

Optimizing the primary treatment of patients with advanced ovarian cancer
by: S. O. Nikogosyan, et al.
Published: (2016-11-01)

A case report of long-term successful use of maintenance therapy with PARP inhibitors in the primary treatment of advanced BRCA-associated ovarian cancer
by: О. N. Churuksaeva, et al.
Published: (2023-09-01)

Tubal Ectopic Pregnancy: From Diagnosis to Treatment
by: Dimitrios Papageorgiou, et al.
Published: (2025-06-01)

HIPEC application potential in the treatment of extensive carcinomatosis in ovarian cancer (retrospective study)
by: S. I. Radostev, et al.
Published: (2024-06-01)

Systemic and tumor-specific inflammatory markers VCAM-1 and ICAM-1 as indicators of extent of surgery and oncologic outcome in advanced ovarian cancer
by: Okan Gultekin, et al.
Published: (2025-09-01)

Comparative analysis of the diagnostyc value of CT and MRI in the assessment of peritoneal carcinomatosis in ovarian cancer
by: Yu. A. Soloveva, et al.
Published: (2025-03-01)

High-Risk Factors and Therapeutic Advances in Ovarian Cancer
by: Xiaoyu SHA, et al.
Published: (2025-07-01)

Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses
by: A. G. Kedrova, et al.
Published: (2016-11-01)

Neoadjuvant chemotherapy for advanced ovarian cancer: literature data and in vitro studies
by: S. A. Kuznetsov, et al.
Published: (2015-09-01)

Optimal cytoreduction for advanced epithelial ovarian cancer
by: N. G. Kormosh, et al.
Published: (2014-08-01)

Primary cytoreductive surgery followed by chemotherapy compared to neoadjuvant chemotherapy followed by cytoreduction as a treatment for stage III and IV ovarian cancer (literature review)
by: E. V. Sibirskaya, et al.
Published: (2024-05-01)

Cytoreductive HIPEC-Combined Surgery in Treatment of Advanced Ovarian Cancer
by: M. V. Zabelin, et al.
Published: (2022-06-01)

Anesthesiological support of cytoreducative operations using hyperthermic intraperitoneal chemotherapy (hipec) in patients with ovaryan cancer
by: D. D. Morikov, et al.
Published: (2019-11-01)

Optimal cytoreductive surgery in patients with disseminated ovarian cancer (the department’s experience)
by: N. G. Kormosh, et al.
Published: (2014-07-01)

DISSEMINATED OVARIAN CANCER: SURGICAL TREATMENT (LITERATURE REVIEW)
by: S. V. Molchanov, et al.
Published: (2016-02-01)

Hereditary breast cancer and ovarian cancer: clinical course and treatment
by: V. V. Semiglazov, et al.
Published: (2021-03-01)

REPEATED OPTIMAL CYTOREDUCTIVE SURGERIES IN COMBINED MODALITY TREATMENT OF OVARIAN CANCER. CASE REPORT
by: S. V. Molchanov, et al.
Published: (2017-07-01)

Remote results of treatment of patients with advanced ovarian cancer after interval and delayed cytoreductive surgery: a retrospective single-center study
by: P. I. Sorokin, et al.
Published: (2025-05-01)

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
by: Theresa L. Werner, et al.
Published: (2018-06-01)

Specific features of current intraperitoneal therapy in patients with ovarian cancer
by: A. G. Kedrova, et al.
Published: (2016-06-01)

New treatment options for bladder cancer patients: based on ASCO 2022 materials and beyond
by: I. V. Zyatchin, et al.
Published: (2022-10-01)

Some Aspects of Postoperative Management of Patients with Ovarian Cancer after Cytoreductive Surgery Using Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
by: D. D. Morikov, et al.
Published: (2022-05-01)

PARP1 inhibitors in breast cancer therapy. Mechanism of action and clinical use
by: D. S. Dolgasheva, et al.
Published: (2020-06-01)

Evaluating the tozzi classification system in diaphragm surgeries for advanced ovarian cancer: Clinical applicability and perioperative outcomes
by: Divya Panyam Vuppu, et al.
Published: (2025-01-01)

Patient-derived ovarian cancer models demonstrate the influence of tumor-associated macrophages on therapeutic response
by: Parisa Nikeghbal, et al.
Published: (2025-12-01)

Comparative characteristics of the effectiveness of therapy with PARP inhibitor in patients with primary ovarian cancer in the Tyumen Region in the period from 2019 to 2023
by: M. Ya. Kuzmenko, et al.
Published: (2025-05-01)

USE OF INTEGRATED DIFFUSION-WEIGHTED MAGNETIC-RESONANCE IMAGING IN PRE-OPERATIVE EVALUATION OF RESECTABILITY OF ADVANCED OVARIAN CANCER
by: A. E. Solopova, et al.
Published: (2017-08-01)

Imunotherapy opportunities in ovarian cancer
by: I. Zh. Shubina, et al.
Published: (2014-07-01)

Modern clinical portrait of ovarian cancer patient in the Novosibirsk region
by: A. V. Tarkhov, et al.
Published: (2025-03-01)

Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study
by: Hua-Hsi Wu, et al.
Published: (2025-08-01)

EXPERIENCE IN APPLYING THE TECHNOLOGY OF CYTOREDUCTIVE SURGERY WITH HYPERTHERMIC INTRAOPERATIVE INTRAPERITONEAL CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH PERITONEAL CARCINOMATOSIS
by: A. V. Shelekhov, et al.
Published: (2018-07-01)

THE VALUE OF CYTOREDUCTIVE SURGERY FOR ISOLATED LYMPH NODE RECURRENCE OF OVARIAN CANCER
by: H. I. Mamajonov, et al.
Published: (2020-07-01)

A clinical case of repeat use of PARP inhibitors in a patient with <i>mBRCA</i>-associated ovarian cancer
by: A. B. Villert, et al.
Published: (2022-09-01)

Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it?
by: Bhatt Aditi, et al.
Published: (2024-07-01)

Preclinical Evaluation of a B7-H3 Targeting Antibody Enhancing NK Cell-Mediated Cytotoxicity for Ovarian Cancer Treatment
by: Hagelstein I, et al.
Published: (2025-07-01)

Bevacizumab in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Risk-Stratified Analysis
by: İrem Öner, et al.
Published: (2025-06-01)

Optimizing patient recovery: prospective study evaluating compliance and clinical outcomes of enhanced recovery protocols in ovarian cancer following cytoreductive surgery with HIPEC
by: Somashekhar S. P., et al.
Published: (2025-05-01)

Next‐Generation HER‐2 Tumor‐Targeted Delivery of the STING Agonist Immune‐Stimulating Antibody Conjugate (ISAC) Improves Anticancer Efficacy and Induces Immunological Memory
by: Gang Wu, et al.
Published: (2025-07-01)

Treatment of patients with brain metastases from ovarian cancer: clinical observation
by: V. B. Karakhan, et al.
Published: (2014-08-01)